Four AHSNs have been awarded funding by the government to help tackle fatal drug deaths across the UK.

As part of the Reducing Drug Deaths Innovation Challenge, which aims to reduce drug-related deaths across the UK, the Office for Life Sciences is investing £5 million in 12 promising projects.

The four projects that the AHSNs are involved in each look to support people at risk of drug deaths through an opioid overdose.

Health Innovation Network, the AHSN for South London has been awarded a portion of the funding to support its work on a feasibility project to examine a proposed ultra-portable fast-dispersal naloxone tablet (an opioid overdose antidote), so that it is always present with an individual called to an overdose emergency.

The project is a collaboration between the AHSN, King’s College London, Catalent, Accord Health, Scottish Drug Forum, Scottish Families affected by Alcohol and Drugs and DrugFAM.

Kent Surrey Sussex AHSN is also supporting people with opiate overdose using naloxone through the Vivisco Smart Revive Beacon for Opiate Overdose collaboration. The collaboration will co-design and prototype an automatic alert system to contact emergency services with GPS location and type of antidote used, which is triggered when a naloxone package is opened.

The AHSN will work in partnership with Vivisco, Forward Trust, Kent County Council and the Southeast Coast Ambulance Service NHS Foundation Trust.

Wessex AHSN is part of a ‘In Time Naloxone’ collaboration that aims to develop an effective emergency response for the distribution of naloxone by drone to prevent opioid overdoses becoming fatal.

The AHSN will work in partnership with the National Programme on Substance Abuse Deaths, HeroTech8, Midlands Partnership University NHS Foundation Trust and the University of Southampton.

West Midlands AHSN is part of a Co-Evaluation Study of Overdose Detection and Response Wristband Technology. The wristband will detect absence in user movements and alert the individual or surrounding people for intervention.

The AHSN will work alongside Midlands Partnership NHS Foundation Trust, Brave, Keele University and Two Saints Housing Association.

Gary Ford Chair of the AHSN Network and CEO of Oxford AHSN said: “Inappropriate opioid use has a devastating impact on people’s health and on their families. Every year over 4,000 people in the UK die from an avoidable drug overdose.

“The AHSN Network is committed in supporting the government address healthcare challenges including its addiction mission, and we’re proud that four AHSNs have been awarded funding as part of regional collaborations.”

Find out more about the Reducing Drug Deaths Innovation Challenge.

  • Collaborating to improve access and equity of care for sickle cell sufferers

    Harriet Smith is the Health Innovation Network's MTFM National Lead for Spectra Optia. In this blog, she outlines the collaborative efforts to improve the support available to people with sickle cell disease, and tackle long standing inequalities. Sickle cell disease (SCD) is a serious and lifelong health condition. People with SCD produce unusually shaped red [...]

  • Until tackling health inequalities becomes business as usual, innovation is our best chance of equity

    Dr Stuart Monk, National Programme Director for the Accelerated Access Collaborative (AAC) Programmes at the Health Innovation Network, talks about the pivotal role of innovation tackling healthcare inequalities in the NHS. At the Royal Society of Medicine’s Tackling Inequalities conference it was clear from the passion in the room that great progress has been made [...]

  • Where health innovation is concerned, 15 approaches are better than one

    Dr Phil Jennings, Vice Chair of the Health Innovation Network and Chief Executive of Health Innovation North West Coast, discusses why the Network’s collective relicensing gives innovation a better chance of success. In any one day in England, 1.2 million people attend a GP appointment, over a quarter of a million people have an outpatient [...]